To evaluate the effects of oncogenic activation in the PI3K pathway on anti-HER2 therapy, we performed in vitro proliferation assays using a HER2 inhibitor, lapatinib, in HER2+ breast cancer cell lines. This evidence concerns the gene ERBB2 and breast cancer.